Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776106 | 0.89 | GLA (0.56) | GLAMAPTMCOLN3CNR2C5AR1 | |
| SCHEMBL21753821 | 0.87 | GLA (0.54) | GLAMAPTMCOLN3CNR2C5AR1 | |
| SCHEMBL4280108 | 0.86 | KEAP1 (0.56) | GLACNR2TAS2R14KEAP1NFE2L2 | |
| SCHEMBL15779581 | 0.85 | GLA (0.51) | GLAMAPTMCOLN3CNR2C5AR1 | |
| SCHEMBL21595413 | 0.85 | GLA (0.51) | GLAMAPTMCOLN3CNR2CA12 | |
| SCHEMBL29597888 | 0.84 | GLA (0.53) | GLAMAPTMCOLN3C5AR1PYCR1 | |
| SCHEMBL12330055 | 0.83 | GLA (0.50) | GLAMAPTMCOLN3CNR2C5AR1 | |
| SCHEMBL19929699 | 0.83 | GLA (0.50) | GLAMAPTCNR2AGERLMNA | |
| SCHEMBL28416450 | 0.82 | GLA (0.52) | GLAMAPTMCOLN3CNR2C5AR1 | |
| SCHEMBL30667705 | 0.82 | GLA (0.49) | GLAMAPTMCOLN3CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798978-A | Toughened polyamide material with high melt strength and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119704786-A | Nylon pipeline and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-116410586-A | Precipitation-resistant high-toughness polyamide composition and preparation method thereof | 万华化学（宁波）有限公司 | 2023-07-11 | — | — | CN | claimed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| CN-119798978-A | Toughened polyamide material with high melt strength and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119704786-A | Nylon pipeline and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| CN-116410586-A | Precipitation-resistant high-toughness polyamide composition and preparation method thereof | 万华化学（宁波）有限公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10287225-B2 | Chain multiyne compound, preparation method and application thereof | XIAMEN UNIVERSITY (CN) | 2019-05-14 | — | — | US | disclosed |
| CN-106279100-B | Chain-shaped polyacetylene compound and preparation method and application thereof | 厦门大学 | 2019-03-08 | — | — | CN | disclosed |
| EP-2274316-B1 | LIGANDS OF ESTROGEN RECEPTORS AND , METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | USTAV MOLEKULARNI GENETIKY AV CR V V I (CZ) | 2013-02-13 | — | — | EP | disclosed |
| US-8334280-B2 | Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them | Ustav Molekularni Genetikv AV CR, V.V.I. (CZ) | 2012-12-18 | — | — | US | disclosed |
| US-8334280-B2 | Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them | Ustav Molekularni Genetikv AV CR, V.V.I. (CZ) | 2012-12-18 | — | — | US | disclosed |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA UK (CZ) | 2011-05-19 | — | — | US | disclosed |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA UK (CZ) | 2011-05-19 | — | — | US | disclosed |
| EP-2274316-A1 | LIGANDS OF ESTROGEN RECEPTORS AND , METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | Ustav Molekularni Genetiky Av Cr, V.v.i. (CZ) | 2011-01-19 | — | — | EP | disclosed |
| US-7750034-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2009135449-A1 | LIGANDS OF ESTROGEN RECEPTORS α AND β, METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | USTAV MOLEKULARNI GENETIKY AV CR, V.V.I. (CZ) | 2009-11-12 | — | — | WO | disclosed |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | GLA 1158/4885MAPT 4179/4885MCOLN3 2049/4885 |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | ESR2, GPER1, ESRRB | GLA 1107/4885MAPT 3802/4885MCOLN3 1858/4885 |
| US-10287225-B2 | Chain multiyne compound, preparation method and application thereof | SQLE, COASY, MCCC2 | GLA 4187/4885MAPT 4110/4885MCOLN3 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.